Rare sequence variants in "high-risk" disease genes often referred as Unclassified Variants (UVs) pose a serious challenge to genetic testing. However, UVs resulting in splicing alterations can be readily assessed by in vitro assays. Unfortunately, analytical and clinical interpretation of these assays is often challenging. Here we explore this issue by conducting splicing assays in 31 BRCA2 genetic variants. All variants were assessed by RT-PCR followed by capillary electrophoresis (EP) and direct sequencing. If assays did not produce clear-cut outputs (Class-2 or Class-5 according to analytical IARC guide-lines), we performed qPCR and/or Minigene assays. The latter were performed with a new splicing vector (pSAD) developed by authors of the present manuscript (Patent P201231427 CSIC). We have identified 3 clinically relevant c.7617+1G>A,, and 27 analytical Class-2 variants (not inducing splicing alterations). In addition, we demonstrate that rs9534262 (c.7806-14T>C) is a BRCA2 splicing quantitative trail loci (sQTL).
indicate clear-cut splicing assay outputs, the first indicating that the variant allele produces the same transcript(s) as the wild-type allele, the latter indicating that the UV allele expresses major PTC transcripts. Class-1 was avoided because splicing analysis outputs per se do not allow discarding a pathogenic role (protein function and/or other biological features might be altered). Most relevant, this 4-tier is not a clinical, but rather an analytical classification scheme. As such, analytical Class-2, Class-3, and Class-4 do not have specific clinical recommendations. In this regard, analytical Class-5 is exceptional, as BRCA2 PTCs are considered clinically relevant per se. The analytical classification guide-lines have been updated recently [Walker et al., 2013] . See Supp. Table 1 for further details.
On practical grounds, quantitative (or semi-quantitative) estimation of aberrant/normal transcripts ratio (as expressed from the UV allele) is mandatory for clear-cut analytical classification [Spurdle et al., 2008; Walker et al., 2013] . Most important, two confounding effects (normal expression from the wild-type allele and selective degradation of PTC transcripts by the NMD pathway) should be mitigated in order to produce robust outputs. For instance, PTC transcripts can be stabilized by performing cell cultures in the presence of cycloheximide (or other NMD inhibitors). Interferences from the wild-type allele can be avoided by developing reporter Minigene assays. Unfortunately, these time-consuming approaches cannot be easily implemented into the routine of a Clinical Diagnostics Laboratory.
Here we show that incorporating capillary EP and direct sequencing of exonic SNPs into the analysis of otherwise conventional splicing assays (RT-PCRs of fresh-blood isolated RNAs) is able to generate clear-cut analytical outputs (so to speak, analytical Class-2 and Class-5 outputs according to the IARC guide-lines). However, we show as well that some variants/carriers demand more specific (and time-consuming) analytical approaches (such as dedicated mini-genes or qPCR). As a proof of principle, we analyzed the influence of 31 BRCA2 variants (Table 1) on splicing (see on-line methods and Supp. Table S2 for further details). In silico predictions are shown in Table 1 (splice sites) and Supp. Table S3 (enhancer and silencers) . However, we performed in vitro splicing assays regardless of in silico predictions. Furthermore, we analyzed not only BRCA2 UVs, but also clinical Class-1 and clinical Class-5 variants. We did it because we are interested in finding not only novel BRCA2 splicing mutations relevant in the clinic, but also non-pathogenic splicing alterations (if any) that might contribute to elucidate the sometimes complex relationship between splicing alterations and disease. Last but not least, we are interested in evaluating whether conventional splicing assays provide clear-cut analytical outputs according to existing guide-lines.
As far as we know, BRCA2 c.682-2A>G is a novel variant not previously reported. Capillary EP analyses in carriers (33 cycles RT-PCR assays) detected (in addition to the full-length) a 264nt peak representing roughly 10% of the overall signal ( Figure 1A ). Interestingly, 45 cycles RT-PCR assays revealed five additional peaks ( Figure 1B ). Size-callings were compatible with exon 9 skipping (264nt peak), and activation of five cryptic acceptor sites (CASs) located in intron 8 and exon 9 (Figures 1B and 1C) . All CASs were supported by in silico predictions ( Figure 1C ). Direct sequencing demonstrated exon 9 skipping, and CAS4 activation ( Figure   1D ). Other CAS activation events were not sequenced due to the low abundance of the corresponding RT-PCR products. These should be considered putative CAS activation events inferred from capillary EP size-calling. Similar peak patterns were observed in four additional variant carriers ( Figure 1E ), but not in control samples (data not shown). Importantly, all aberrant splicing events produce PTC transcripts. Segregation analysis together with direct Both studies detected exon 15 skipping (a PTC event) in variant carriers, but bi-allelic wildtype expression was not investigated (analytical Class-4 outputs). Yet, co-segregation studies performed in Danish families supported a pathogenic role for this variant . We have performed splicing assays in 6 BRCA2 c.7617+1G>A carriers. As shown in Supp. Figure S2 , capillary EP analysis (33 cycles RT-PCR) detected, in addition to the fulllength, a 182nt shorter peak compatible with exon15 skipping. Direct sequencing confirmed the skipping event (Supp. Figure S2 ). Capillary EP data (semi-quantitative) shows roughly identical expression levels of full-length and ∆15 transcripts. The data is compatible with the UV allele causing complete (or near complete) exon skipping, but does not prove it. This is so because capillary EP estimates (at best) the ratio between steady-state levels (accumulation) of wild-type and variant transcripts in carriers. This in turn might reflects a combination of multiple underlying processes, including reduced (or unusually higher) transcription rate from the UV allele, instable (or unusually stable) UV transcripts, and wild-type transcripts arising from the UV allele. Yet, segregation analysis together with direct RT-PCR sequencing at one informative locus (rs1799955) revealed that full-length BRCA2 expression was indeed wildtype allele specific (Supp. Figure S2) . Overall, the data qualifies for inclusion into analytical Class-5 (see Supp. Table 1) . We have identified eight Spanish families carrying BRCA2 c.7617+1G>A (Supp. Figure S3 ). Genotyping of STRs and SNPs markers detected a common haplotype in carriers from all eight families, suggesting a founder effect (Supp . Table S4 ).
BRCA2 c.8954-5A>G has been identified recently in Spanish Hereditary Breast and Ovarian
Cancer families [de Juan Jimenez et al., 2013] , but splicing defects if any) were not investigated. The change is reported in the Universal Mutation Database (UMD) as a clinical Class-3 variant (http://www.umd.be/BRCA2/). We have performed splicing assays in two BRCA2 c.8954-5A>G carriers. Agarose gel electrophoresis showed a single RT-PCR product both in controls and carriers (data not shown), but capillary EP detected an additional peak (+4nt) in carriers (Supp. Figure S4 ). Direct sequencing revealed a PTC transcript in which the last 4nt of intron 22 have been incorporated into BRCA2 exon 23 (Supp. Figure S4 ).
Measured by capillary EP, the aberrant mRNA represents roughly 30% of the overall signal. The data is compatible with wild-type expression arising from the UV allele, but does not prove it (as discussed above). Since bi-allelic wild-type expression was not tested due to lack of informative loci, it is not possible to classify the output into any specific analytical category (Class-4 or Class-5?) according to the 2008 guide-lines. However, the very same output qualifies for analytical Class-4 according to the 2013 guide-lines (see Supp. Table 1) .
Interestingly, HSF analysis predicted a de novo acceptor site at position c.8954-4 without disrupting exon 23 native acceptor site (Table 1) , thus suggesting a mechanism through which c.8954-5A>G might indeed contribute to normal splicing. To investigate wild-type expression arising from the UV allele, we used a reporter Minigene assay (see on-line methods). The analysis revealed that c.8954-5G does not produce full-length mRNA (Supp. Figure S5 ). As a whole, our data qualifies for inclusion into analytical Class-5. We have identified four Spanish families carrying this mutation (Supp Figure S6) . Haplotype analysis identified a 1.28Mb shared haplotype in all carriers, suggesting a founder effect (Supp . Table S4 ).
Similar assays performed in 23 additional BRCA2 variants did not detect aberrant transcripts, despite the fact that we used high sensitivity capillary EP analysis. BRCA2 bi-allelic expression was confirmed in all cases (Supp. Figures S7 to S18 ). Taking together, all 23 studies qualify for inclusion into analytical Class-2 (see Supp. Table 1 ). Yet, it is important to remark that analytical Class-2 per se do not have a definite role in the clinical classification of BRCA2 variants.
Not surprisingly, splicing analysis tends to be overlooked in BRCA2 PTC mutation carriers.
However, these (as other mutations) might induce splicing alterations (perhaps even regenerating a full-length open reading frame). This phenomenon is probably unlikely, but is certainly real. For instance, it has been reported that c.145G>T (p.Glu49Ter), a PTC mutation located in BRCA2 exon 3, enhances exon 3 skipping (an in-frame splicing isoform), illustrating a complex interplay between RNA and protein effects of potential clinical interest [Sanz et al., 2010] . We have included in our analysis five BRCA2 variants predicted to express PTC transcripts, including four pathogenic (clinical Class-5) mutations (c.1773_1776del, c.3264dupT, c.8010_8032del22, and c.9026_9030del 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We have identified five common (MAF>0.1) BRCA2 variants in our cohort (Table 1) . In silico analyses did not predict splicing alterations, with the single exception that (according to MaxEnt), c.7806-14T>C (rs9534262) produces a slight reduction of the exon17 acceptor site score (Table 1) . Interestingly, two "naturally occurring" alternative splicing events (∆17,18 and ∆18) have been described in this region [Walker et al., 2010] . Capillary EP did not detect novel transcripts in c.7806-14T>C carriers, but suggested that BRCA2 ∆17,18 was slightly upregulated (data not shown). Hence, we decided to explore the role of c.7806-14T>C in alternative splicing regulation by qPCR (see on-line Methods). Quantification experiments were performed in 7 T/T, 20 T/C, and 11 C/C carriers. The expression level of BRCA2 ∆17,18 (relative to overall BRCA2 expression level) was low (∆C T = 5.19±0.59), reflecting the fact that BRCA2 ∆17,18 is a minor alternative splicing isoform. Yet, the ANOVA test identified differences associated with each genotype (p=0.006). Post-hoc test demonstrated higher levels of BRCA2 ∆17,18 in C/C carriers compared with T/T carriers (p=0.004) (Supp. Figure   S21 ). To confirm that the C allele is indeed functionally related, and not just in linkage disequilibrium with a true splicing regulatory element, we performed further analysis in a reporter minigene (exons 16 to 20 of BRCA2) based on the new splicing vector pSAD® (Consejo Superior de Investigaciones Científicas). In this model, the c.7806-14C reporter minigene showed relative increased levels of both ∆17,18 and ∆18 isoforms if compared with c.7806-14T reporter minigene (Supp. Figure S22) . Overall, the data indicates that rs9534262 is a bonafide BRCA2 splicing quantitative trait locus (sQTL). Since BRCA2 ∆17,18 and BRCA2 ∆18 are PTC splicing isoforms, we hypothesized that rs9534262 might be associated Table 1 ). However, BRCA2 rs9534262 is a clinical Class-1 variant (MAF is close to 0.5 in many populations). Similarly, splicing analysis in c.9976A>T (p.Lys3326Ter) carriers produced an analytical Class-5 output, despite the fact that this is a clinical Class-1 variant based on posterior probability analysis (http://brca.iarc.fr). These two examples illustrates the fact that the 4-tier classification scheme of splicing assays outputs is more related to the "analytical quality" and "interpretation" of UV splicing assays than to the actual probability of being pathogenic.
Undoubtedly, sequencing informative exonic SNPs (testing bi-allelic expression) is critical in order to produce clear-cut routine in vitro splicing assays. In addition, we show that incorporating capillary EP into the analysis provides highly informative analytical data (both high-resolution size-calling and high-sensitivity detecting RT-PCR products). These two features were critical in order to characterize the rather complex splicing outcome observed in BRCA2 c.682-2A>G carriers. This variant induces the expression of several (probably six) different aberrant transcripts. As a result, the "aberrant signal" is split into different components We have performed several routine in vitro splicing assays in carriers of UV variants with low prior probability (according to in silico predictions) of finding an alteration; a conservative approach that we nonetheless recommend in the clinical setting. Undoubtedly, in silico analyses might provide high accuracy predictions, but they do not detect all splicing defects, especially in variants located outside the 5' and 3' consensus sites (Houdayer et al., 2012 ).
Yet, we think that in silico analyses have important roles in the clinic. For instance, they assist with prioritizing variants for dedicated splicing assays (such as reporter Minigenes) in cases where routine assays do not produce clear-cut outputs, or in cases in which routine assays are not feasible (i.e. lack of fresh blood RNA).
In conclusion, we show that incorporating capillary EP and direct sequencing of exonic informative SNPs to, otherwise, conventional fresh blood-based RT-PCR splicing assays often provides high-quality results that allow systematic analytical classification according to existing guide-lines. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w .25 no effect no effect
.14 no effect no effect ----c.6825G>A (p.Glu2275=) ‡ -.0004 no effect no effect -Class-2 -- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The BRCAX cohort has been extensively described elsewhere [de Garibay et al., 2013; Dosil et al., 2010] . All participants signed an informed consent. The study was approved by the Ethics Committee of the participating institutions.
BRCA2 sequence variants description.
All BRCA2 genetic variants are described according to HGVS guide-lines (http://www.hgvs.org/mutnomen). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the GeneBank reference sequence NM_000059.3
In silico splice predictions
Consensus splice sites predictions were performed with HSF and MaxEnt algorithms.
Splicing enhancer predictions were performed with ESE finder, RESCUE-ESE, PESE and EIE algorithms. Similarly, splicing silencer predictions were analyzed with ESS, Fas-ESS, PESS and IIE algorithms. All analyses were performed on-line with Human Splicing Finder version 2.4.1 (default settings). 
Minigene assays

Construction of Minigenes:
The construction of the minigene containing BRCA2 exons 23 and 24 and flanking intronic sequences (MGBR2_Ex23-24) inserted into the splicing vector pSPL3b was previously 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Site directed mutagenesis:
Mutagenesis was carried out according to the PCR mutagenesis protocol 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
RT-PCR of minigenes:
Retrotranscription was carried out with 200 ng of RNA and the transcriptor first strand cDNA synthesis kit (Roche Diagnostics). Fluorescent RT-PCRs were performed in triplicate in a final volume of 20 µL that contained 2 µL of cDNA and the flanking primers of constitutive exons of pSPL3, SD6-PSPL3_RTFW (FAM-5' TCACCTGGACAACCTCAAAG 3') and SA2-PSPL3_RTREV (5' TGAGGAGTGAATTGGTCGAA 3'). Samples were denatured at 94°C for two minutes, followed by 25-30 cycles consisting of 94°C for 20 seconds, 58°C for 20 seconds, and 72°C for 30-90 seconds, and a final extension step at 72°C for two minutes.
The PCR products were analyzed by capillary electrophoresis. Expected sizes of the RT- Therefore, ∆C T reflects the expression level of BRCA2 ∆17,18 relative to the overall expression level from the same locus. ∆C T was analyzed in triplicate in all tested samples.
Haplotype analysis of recurrent variants
Haplotype analysis was performed with up to 9 short tandem repeats (STR) covering 14.4Mb of chromosome 13 surrounding the BRCA2 gene. Primer sequences, order of markers and physical distances among D13S260, D13S1699, D13S1698, D13S1697, D13S1701, D13S1715, D13S1493, D13S267, and D13S1694 were obtained from the Ensembl database (http://www.ensembl.org). Polymerase chain reaction (PCR) products of STR markers were generated using fluorescently labelled primers. Size-calling was performed by capillary electrophoresis. Additionally, 3 BRCA2 SNPs (rs1799943, rs144848, and rs9534262) were genotyped by HRMA. Figure S1 . A family carrying the BRCA2 variant c.682-2A>G is displayed. Segregation analysis allowed us to determine the phase between the variant allele and two SNPs located in BRCA2 exon 10 (rs9534262) and exon14 (1799955). Direct sequencing of RT-PCR assays (33-cycle PCR) performed with RNA isolated from individual ID_1 showed that mutant allele contribution to overall BRCA2 expression (if any) is minimal.
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John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure S2 . A, B) capillary EP analysis (33 cycles RT-PCR) revealed an aberrant transcript 182nt shorter than wt in c.7617+1G>A carriers, suggesting BRCA2 exon 15 skipping. Direct sequencing confirmed exon 15 skipping. C) An informative locus in exon 14 (rs1799955) allowed us to demonstrate that the variant allele does not contribute to full-length expression.
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Note that RT-PCR products generated with an exon15 reverse primer (right) are full-length specific. Segregation analysis allowed us to determine the phase between the variant allele and rs1799955 (data not shown).
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F o r P e e r R e v i e w
Supp. Figure S3 . Eight Spanish families carrying the BRCA2 genetic variant c.7617+1G>A. Numbered Individuals were included in the haplotype analysis (See Supp. Table S2 ).
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Supp. Figure S6 . Four Spanish families carrying the BRCA2 genetic variant c.8954-5A>G. Numbered Individuals were included in the haplotype analysis (See Supp. Table S3 ).
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Human Mutation
Page 31 of 50
John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure S10 . Capillary EP analysis of RT-PCR assays performed with primers located in exons 7 and 10 shows the presence of a single transcript both in wt controls and one c.681+69C>T carrier. Bi-allelic expression was confirmed by direct sequencing (reverse strand) of RT-PCR assays containing an informative locus in exon 14 (rs1799955). Figure S21 . qPCR analysis of BRCA2 ∆17,18 splicing isoform using BRCA2 exon 24 expression (a proxy for overall BRCA2 expression level) as an endogenous control. ∆C T = (C T BRCA2 ∆17,18 -C T BRCA2 exon24). 7 T/T, 20 T/C, and 11 C/T samples were analyzed in triplicated. Statistically significant differences betwen C/C and T/T genotypes were observed (BRCA2 ∆17,18 is upregulated in C/C carriers). Quantification in T/C carrirers is compatible with a dosage effect. Overall, the data indicates that rs9534262 (c.7806-14T>C) modulates BRCA2 alternative splicing. Figure S22 . Minigene analysis of BRCA2 ∆18 and ∆17,18 expression level using BRCA2 full-lenght as an internal reference. Relative signal=(peak area splicing isoform/peak area full-lenght). BRCA2 ∆17,18 and BRCA2 ∆18 are upregulated in rs9534262 C minigene. The variant allele produces major transcript(s) carrying a PTC, or inframe deletions disrupting known functional domain(s)
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The variant allele produces only transcript(s) carrying a PTC, or in-frame deletions disrupting known functional domain(s), determined by semi-quantitative or quantitative methods. 4
The variant allele produces minor transcript(s) carrying a PTC, or inframe deletions disrupting known functional domain(s), at higher level than similar transcripts corresponding to physiological alternative splicing, or absent in wt controls.
The variant allele produces aberrant transcript(s) carrying a PTC, or in-frame deletions disrupting known functional domain(s), these transcripts are not found in controls assayed in tandem, but further assessment to determine if the UV allele does or does not contribute to production of wildtype transcript. 3
The variant allele produces major or minor transcript(s) carrying an inframe deletion not disrupting known functional domain(s), at a higher level than similar transcripts corresponding to physiological alternative splicing.
All other transcript patterns e.g. the variant allele produces transcript(s) carrying an in-frame deletion not disrupting known functional domain(s), variant allele upregulates transcripts corresponding to physiological alternative splicing, at least some of which do not carry a PTC or are not an in-frame deletion disrupting known functional domains. 2
The variant allele produces the same transcript(s) as the wildtype allele. The variant allele produces transcript patterns comparable to that of wildtype controls assessed in tandem.
1 [Spurdle et al., 2008] , 2 [Walker et al., 2013] In 2008, the IARC proposed a classification system aimed to achieve robustness in the analytical interpretation of in vitro splicing assays. The scheme has been up-dated recently. Somehow inevitably; these guide-lines introduce vague terms such as major, minor, or comparable (highlighted in bold italics by authors of the present report). Note that the 2008 original guide-lines describe splicing assay outputs, while the update is more concerned with methodological issues. By doing so, the meaning of the classification system has been slightly modified. For instance, analytical Class-4 does not reflect any more UV alleles expressing both wild-type and PTC transcripts, but a mere lack of analytical information (the UV contribution to wild-type expression has not been tested). Note that analytical guide-lines do not make a distinction between PTCs located 5' or 3' to the last 50 nucleotides of the penultimate exon, despite the fact that this might have clinical relevance. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
